Navigation Links
Single flexible sigmoidoscopy screening associated with reduced colorectal cancer
Date:8/18/2011

A single flexible sigmoidoscopy screening between the ages of 55-64 years is associated with a lower level of colorectal cancer (CRC) incidence and mortality, according to a study published online August 18 in the Journal of the National Cancer Institute.

Multiple randomized controlled trials have shown that fecal occult blood testing (FOBT) in CRC screening can reduce the mortality rate of patients diagnosed with CRC. Observational studies and a prior, randomized trial from the U.K., known as SCORE have shown a reduction in incidence and mortality for cancer in the rectum and sigmoid colon (distal CRC) among patients who had undergone endoscopy, suggesting that the removal of adenomas at screening can provide long-term protection against the development of distal CRC.

To determine if single flexible sigmoidoscopy is a good preventative measure in CRC screening, the researchers, coordinated by Nereo Segnan, M.D., of the Epidemiology Unit at S. Giovanni University Hospital in Turin, Italy, mailed a questionnaire investigating about subject's interest in FS screening to a random population sample of men and women between the ages of 55-64 years. Eligible interested responders were randomly assigned to either the control group (N= 17148 - no further contact) or intervention group (N=17144 - invitation for flexible sigmoidoscopy)

Flexible sigmoidoscopy was performed on 9,911 subjects, and of those, 9,387 (94.71%) were discharged, 55 (0.55%) were referred for surgery, 395 for follow-up surveillance colonoscopy, and the remaining 74 patients did not comply with the recommended total colonoscopy assessment.

The median follow-up period was 10.5 years for CRC incidence and 11.4 years for all-cause and CRC-specific mortality. During this period 557 people (including those detected at initial screening) were diagnosed with a CRC and 148 died of the disease.

The researchers found that in the intent-to-treat analysis, CRC incidence and mortality were reduced by 18% and 22%, respectively. CRC incidence was reduced by 31% among those who were screened (per protocol analysis), and by 46% for advanced CRC cases.

Furthermore, CRC mortality was statistically significantly reduced by 38% in screened subjects compared to the control group.

The authors write that the reported findings, which are consistent with the observed reduction of CRC incidence and mortality among people screened in the recently published UK Flexible Sigmoidoscopy Screening Trial, support the hypothesis that "Flexible sigmoidoscopy screening offered just once represents a safe and effective method for CRC screening and ensures a long lasting reduction of CRC risk." According to the researchers, "A longer follow-up is needed to fully assess the impact on mortality and to estimate the duration of the protective effect."

In an accompanying editorial, Timothy R. Church, Ph.D., of the University of Minnesota, writes about what the best approach to CRC screenings may be. Underlying the three main CRC tests (flexible sigmoidoscopy, FOBT, and colonoscopy), Church mentions that a cost-effective analysis is an important factor in determining the best available method, stating, "these costs are driven by not only the up-front infrastructure costs for laboratories, equipment, endoscopy facilities, training, and manufacturing but also by the rates of false-positive results."

Church argues that since none of the standard three approaches to CRC screening is more effective than the other, until more substantial evidence is collected, endorsing all three methods is the best way to attack CRC. In the event of conflicting results from the tests, Church writes: "Any concerns about the potential confusion that arises from multiple approaches may be balanced by the advantages of tailoring screening to the preferences of the patient."


'/>"/>

Contact: Zack Rathner
jncimedia@oxfordjournals.org
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Single traumatic brain injury may prompt long-term neurodegeneration
2. Single Reading Cant Gauge Blood Pressure Control: Study
3. Single moms entering midlife may lead to public health crisis
4. Single bioptic telescope for low vision driving may not obscure road view of second eye
5. Single Gene Linked to Evolution of Human Brain
6. Advanced technology reveals activity of single neurons during seizures
7. Single gene defect causes brain tumor
8. See how they grow: Monitoring single bacteria without a microscope
9. Cancer in a single catastrophe
10. Scientists Aim for Test That Spots Single Cancer Cell in Blood Sample
11. Scientists Aim for Test That Could Spot Single Cancer Cell in Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... 10 Best Water is excited to announce ... brand owners that topped the list as a result of their commitment to offering ... brand was Tibet 5100, a top notch water company that specializes in providing the ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... February 10, 2016 , ... IDEX Health & ... PEEK-lined stainless steel (PLS) columns combine the strength of traditional stainless steel with ... of biological samples while operating at ultra-high pressures of 20,000 psi. The higher ...
(Date:2/10/2016)... Washington, DC (PRWEB) , ... February 10, 2016 , ... ... highest level since the start of Medicare Part D a decade ago, according to ... collecting comments from older adults on how they are coping with rapidly rising costs. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 10, 2016  Astellas Pharma Inc. (TSE: 4503, ... today that it has successfully completed, through its indirect ... to purchase all issued and outstanding shares of common ... CEO: Paul Wotton , "Ocata") for a price ... cash ("Tender Offer"). Astellas commenced the Tender Offer on ...
(Date:2/10/2016)... , Feb. 10, 2016  The ... Nursing received an in-kind gift from ... a VeinViewer® Vision vein finder for the ... help students as they learn how to ... technology with traditional technique. ...
(Date:2/10/2016)... , Feb. 10, 2016 ... synergistic confluence of various technologies that results ... previously unavailable. These opportunities create a cyclical ... in turn, drives the development of new ... is characterized by technology convergences, which are ...
Breaking Medicine Technology: